Leprosy in England and Wales 1953-2012: surveillance and challenges in low incidence countries by Fulton, N et al.
Leprosy in England and Wales
1953–2012: surveillance and challenges
in low incidence countries
Nicholas Fulton,1 Laura F Anderson,1 John M Watson,1 Ibrahim Abubakar1,2
To cite: Fulton N,
Anderson LF, Watson JM,
et al. Leprosy in England and
Wales 1953–2012:
surveillance and challenges in
low incidence countries. BMJ
Open 2016;6:e010608.
doi:10.1136/bmjopen-2015-
010608
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-010608).
Received 19 November 2015
Revised 26 January 2016
Accepted 3 March 2016
1Respiratory Diseases
Department, Public Health
England, London, UK
2Research Department of
Infection & Population
Health, UCL
Correspondence to
Professor Ibrahim Abubakar;
Ibrahim.Abubakar@phe.gov.uk
ABSTRACT
Objective: To review all notified cases of leprosy in
England and Wales between 1953 and 2012.
Design: National surveillance study of all reported
cases.
Setting: England and Wales.
Outcome: Number and characteristics of reported
cases.
Results: During this period, a total of 1449 leprosy
cases were notified. The incidence fell from 356 new
cases notified between 1953 and 1962 to 139 new
cases between 2003 and 2012. Where data were
available, leprosy was more common in men,
15–45 year olds and those from the Indian
subcontinent. There was considerable undernotification
in 2001–2012.
Conclusions: The high level of under-reporting
indicates a need for improved surveillance in the UK.
Public Health England, in collaboration with the UK
Panel of Leprosy opinion, has revised the UK
Memorandum on Leprosy in order to provide updated
guidance on diagnostic procedures, treatment, case
management, contact tracing and notification.
INTRODUCTION
Leprosy is a curable infectious disease caused
by the bacillus Mycobacterium leprae, which
predominantly affects the skin and superﬁ-
cial nerves. It is a leading global cause of per-
manent disability from infectious disease.1 2
Although historically patients with leprosy
have been subject to stigma based on exag-
gerated perceptions of infectiousness,3
leprosy is not a particularly infectious
disease; only about 5% of spouses of lep-
romatous patients develop clinical leprosy.4
The WHO elimination target of less than
one leprosy case per 10 000 population was
met in 2000.1 Since then the global preva-
lence of leprosy has decreased from approxi-
mately 600 000 cases in 20015 to <200 000 in
2015.6 The signiﬁcant decrease in prevalence
since the late 1990s is due in part to the
halving of the period required to complete
treatment for leprosy to 12 months,2 7 8
resulting in fewer people being treated at
any one time. In 2014, the highest numbers
of new cases were in India, Brazil and
Indonesia, which reported more than 10 000
cases.7
In European Union countries, only a small
number of leprosy cases are reported each
year.9–11 Autochthonous transmission is infre-
quent; the last conﬁrmed case of transmis-
sion within the UK was in 1954.12 A report
from France, however, suggests that transmis-
sion in a western European country can still
occur.13 Leprosy has been a notiﬁable
disease in England since 1951 but, due to
low incidence, the importance of national
surveillance has been perceived to be low
and under-reporting is likely to have
occurred.14 Notiﬁcation of cases ensures that
patients are referred to clinicians experi-
enced in leprosy diagnosis and treatment
(known as Consultant Advisors in Leprosy in
the UK), and that timely contact tracing
around infectious cases is carried out.
Surveillance data are also important for mon-
itoring the disease burden and epidemiology
of UK leprosy to allow appropriate targeting
of resources.
To improve leprosy case management and
notiﬁcation, Public Health England (PHE)
has revised the Memorandum on Leprosy,
which was previously published in 1997.15
This provides guidance updates on diagnosis
and treatment of patients with leprosy,
Strengths and limitations of this study
▪ National surveillance study including all notified
cases; however, in recent years, there has been
undernotification of cases.
▪ The extent of clinical information reported on
each case is limited.
▪ First summary of leprosy epidemiology in the UK
for over 15 years describing trends and
characteristics of cases.
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together with case notiﬁcation procedures and surveil-
lance.4 This report reviews the current epidemiology of
leprosy in England and Wales, the shortcomings in
recent surveillance and the measures implemented to
strengthen surveillance and control of this rare infec-
tious disease.
METHODS
All notiﬁed cases of leprosy in England and Wales
between 1953 and 2012 were reviewed using national
surveillance data held by PHE.14 Sociodemographic and
clinical details are collected by PHE centres in close
liaison with the managing clinician using the standar-
dised leprosy notiﬁcation form and include age, sex,
country of birth and type of disease. An audit of data
was carried out for the years 2001–2012 to determine
completeness of case numbers, given concern about
under-reporting during this period. This was done by
cross-referencing the numbers reported in the national
leprosy database with data from specialist leprosy
centres. Additional cases identiﬁed from these centres
were added to national surveillance if they had not ori-
ginally been reported, but sociodemographic and clin-
ical details were not available for these patients.
Incidence rates per 100 000 population were calcu-
lated using Ofﬁce for National Statistics mid-year popula-
tion estimates as denominators16 (2011 estimates were
also used for 2012) and presented with 95% CIs.
Proportions and numbers of cases reported between
1953 and 2012 were calculated. Figures by type of
disease (tuberculoid/borderline tuberculoid (few skin
lesions containing low numbers of bacilli) and leproma-
tous/borderline lepromatous (a more infectious form
where numerous lesions and bacilli are present)) and
demographic characteristics were presented for 1983–
2012, where data were available. Signiﬁcant changes in
the number of leprosy notiﬁcations over time were
examined using a χ2 test for trend. p Values of less than
0.05 were considered statistically signiﬁcant. Statistical
analyses were performed using STATAV.12.0.
RESULTS
Between 1953 and 2012, a total of 1449 leprosy cases
were notiﬁed in England and Wales. The incidence fell
from 356 new cases notiﬁed between 1953 and 1962
compared with 139 new cases between 2003 and 2012
(χ2 test for trend p<0.01). Rates decreased from 0.079
(95% CI 0.071 to 0.087) new cases per 100 000 popula-
tion in 1953–1962 to 0.024 (95% CI 0.02 to 0.028) new
cases per 100 000 population in 2003–2012. The decline
in rates and numbers of cases has slowed compared with
the large decreases seen between 1963–1972 and 1983–
1992 (ﬁgure 1). Of the 159 cases reported between 2001
and 2012, 57.8% (92/159) had not been notiﬁed and
were identiﬁed as a result of the audit. Despite this, all
of these patients were treated by a specialist leprosy
clinician.
Between 1983 and 2012, 396 leprosy cases were
reported in England and Wales. For cases with known
clinical information, 44.7% (119/266) were diagnosed
with lepromatous or borderline lepromatous leprosy
(ﬁgure 2). For those with a recorded sex at notiﬁcation,
63.9% (182/285) were male, and of those with a known
age, 64.6% (148/229) were aged 15–44 years. Almost
60% (128/222) of cases with a recorded country of birth
were born in South Asia, with the most common coun-
tries being India (72) and Bangladesh (24).
DISCUSSION
The decreasing global trend in leprosy rates and notiﬁca-
tions since the 1950s has also been seen in England and
Wales. Despite this, as with the global ﬁgures, England
and Wales leprosy incidence reductions have slowed in
the last decade.2 6 The slight increase in case report
numbers seen in 2003–2012, compared with 1993–2002,
probably reﬂects under-reporting in the earlier decade;
82.6% (76/92) of the cases identiﬁed in the 2001–2012
audit were 2003–2012 cases (making 54.7% (76/139) of
the 2003–2012 cases). Therefore, the 1993–2002 period
is likely to have under-reporting as it did not have the
same level of correction for missing cases.
Figure 1 Case reports and rates
reported to national leprosy
surveillance, England and Wales,
1953–2012 (N=1449).
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The high proportions of cases that were male and
15–44 years old may reﬂect the reported increased risk
of leprosy in men after puberty,17 or alternatively the
demographic features of immigrants to the UK from
high incidence countries. The large proportion of UK
patients with leprosy that were born in South Asia
reﬂects the high levels of migration from this region
compared with other world regions, together with the
high leprosy burden in these countries.6
The signiﬁcant level of under-reporting in 2001–2012
highlights the current shortfalls in leprosy surveillance
and reporting systems in the UK. This may have implica-
tions for case management and resource distribution in
the future, particularly if the lack of complete surveil-
lance and clear protocols for leprosy cases contributes to
low clinical expertise, and misdiagnosis/underdiagnosis
of cases. Although not reported to PHE by the clinician
making the initial diagnosis, the cases identiﬁed during
the audit had been managed by a Consultant Advisor in
Leprosy. This suggests that although diagnosing clini-
cians appeared to be aware that patients should be
treated by a specialist physician, they were unaware of
the requirement to notify or the notiﬁcation procedure.
Owing to the rarity of leprosy in the UK, however, and
consequent low clinical awareness, it is possible that
further cases were not identiﬁed. These unidentiﬁed
cases may not have received the highest standard of
treatment, in view of the failure to refer to a Consultant
Advisor in Leprosy, and appropriate contact tracing may
not have been carried out.
In addition to a probable underestimate of total case
numbers due to under-reporting, there is also a lack of
UK data on key WHO indicators for assessing leprosy
burden reduction, such as type of disease, and the pres-
ence of grade 2 disabilities (deﬁned as visible damage to
the hands and feet, such as wounds, claw hand and loss
of tissue4). Despite surveillance data from the WHO
indicating continued global decreases in leprosy preva-
lence and incidence, comprehensive surveillance on the
key indicators from all world regions is also necessary to
monitor progress towards further burden reduction
targets. Recent WHO reports indicate that leprosy data
are not available for most of Europe, North America
and numerous countries in Asia.18 This UK report and
audit of cases will contribute to European ﬁgures for
WHO assessment, and highlights the potential for other
European countries to provide similar data. Complete
case reporting in other parts of Europe will also enable
a better understanding of the impact of changes in
countries with the highest leprosy burden and shifting
migration patterns over time on the epidemiology of
leprosy in Europe.10 11 19
As the incidence of leprosy further decreases, there is
a risk that the number of clinicians with expertise in its
management will diminish.20 Future clinical training in
leprosy management needs to be addressed in the UK
and across Europe if a high standard of patient care is to
be maintained.
As leprosy is rare in the UK, it is important to increase
healthcare workers’ awareness of the disease to ensure
that patients do not experience stigma and delayed diag-
nosis.10 20 21 Increased clinical understanding will allow
rapid diagnosis and appropriate treatment from, or in
conjunction with, an experienced Consultant Advisor in
Leprosy. This will help reduce the likelihood of severe
neurological damage and grade 2 disabilities and ensure
that timely contact tracing around infectious cases is
carried out to prevent the possibility of onward transmis-
sion. Public and healthcare worker access to updated
leprosy information, and clear guidance on public
health action around leprosy, will enable an increased
understanding of leprosy and its low infectiousness. This
will help to consolidate efforts by leprosy organisations
to dispel stigma around leprosy.10 22 23
PHE, in collaboration with the UK Panel of Leprosy
opinion, has revised the Memorandum on Leprosy4 in
order to provide the most up to date national guidance
on diagnostic procedures, treatment, case management,
contact tracing and notiﬁcation. In addition to a recom-
mended code of practice for case management and
Figure 2 Number of leprosy cases by type, England and Wales, 1953–2012 (N=1449).
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notiﬁcation, it outlines the natural history of leprosy, and
lists contact details of specialist Consultant Advisors in
Leprosy and sources of further information. The
Memorandum outlines steps that have been taken to
strengthen and simplify national surveillance while safe-
guarding patient conﬁdentiality. The Memorandum is
published on the PHE website and revised as needed to
keep abreast of changes in advice on clinical and public
health management as well as relevant changes to the
health service.
The prevalence of leprosy in high-income countries is
extremely low. Nevertheless, national surveillance
systems need to be robust and reliable so as to identify
all cases and reduce the likelihood, however unex-
pected, of onward transmission. Health services in low
prevalence parts of the world, such as Europe, should
continue to support the maintenance of clinical and
public health expertise, surveillance, and research into
leprosy in order to contribute to further reducing the
global burden of leprosy.
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